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Abstract
PC-3 prostate adenocarcinoma cells were injected subcutaneously in the
hind leg of female Balb/c nude mice. After a few weeks of tumor growth,
200 µL of a solution containing gas bubbles stabilized by PBCA nanoparti-
cles encapsulating nile red was intravenously administered. The mice were
then divided into four treatment groups, three of which were treated with
ultrasound, while the last group was not. The three different ultrasound
treatments were (1) 1 MHz and MI = 0.1, (2) 1 MHz and MI = 0.4, and (3)
1 MHz and MI = 0.4 + 5 MHz and MI = 2.24. Blood vessels were stained us-
ing FITC-lectin. Freeze sections from the tumors were prepared and imaged
in a confocal microscope. The images were quantitatively and qualitatively
analyzed. No statistical difference was found between the different treat-
ment groups from the quantitative analysis, as the standard deviations were
too large. However, a qualitative difference could be observed between mice
that were not treated with ultrasound and mice that were treated. It was
concluded that the uptake in adipose tissue seemed to be improved after
ultrasound.
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1 Introduction
Cancer is a devastating disease and a leading cause of death worldwide [38]. The
major disadvantage related to conventional cancer therapy is that it is not specific.
Conventional chemotherapeutics are toxic to all cells, thereby not only destroying
cancerous cells, but also healthy tissue. In addition, chemotherapeutics can have
quite serious side effects, e.g. heart damage with Doxorubicin. To limit the amount
of side effects experienced by the patient, the dose given to the patient must be
controlled. Limiting the dose comes at the expense of the amount of drug that
reaches the actual pathological site, and hence the effect of the therapy.
Nanoparticles have the potential to aid in this respect. By using nanoparticles
as drug carriers, the treatment can be made more tumor specific. Due to their
large size, intravenously administered nanoparticles extravasate from the relatively
large pores of blood vessels in tumors, and accumulate in the cancerous tissue. This
is termed passive targeting. At the same time the nanoparticle carrier protects
the healthy cells from the drug, meaning that the side effects are reduced. This
again means that the chemotherapeutic dose can be increased and the therapy
becomes more effective. By actively targeting the nanoparticles to certain cells by
functionalizing them with ligands, the treatment can be made even more specific
depending on tumor type.
Although the nanoparticles accumulate in the tumor interstitium, getting them to
the cancerous cells is challenging as there are several factors hindering them. One of
the largest obstacles is the high interstitial pressure of the tumor. Ultrasound can
be used to help overcome the physical barriers for the nanomedicine and works by
one or more of three mechanisms: hyperthermia, cavitation and radiation pressure.
In combination with microbubbles, ultrasound has been shown to improve drug
delivery.
In this report, confocal microscopy data from mice having received microbubbles
made from a shell of PBCA nanoparticles encapsulating nile red, in combination
with ultrasound therapy, is reviewed. The aim is to investigate how different
ultrasound treatments affects the distribution of nanoparticles in tumor tissue.
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2 Theory
2.1 Nanoparticles
Traditionally, nanoparticles are defined as particles with sizes up to 100 nm.
In practice, however, particles larger than this are included in the definition.
Nanoparticles possess some unique properties that their bulk equivalents do not,
such as the small size, large surface area to volume ratio and high reactivity [51].
These properties may be utilized in medicine to overcome some of the limitations
of traditional therapeutic and diagnostic agents [51]. Nanoparticles may have dif-
ferent shapes and may be constructed of different materials. They may be used
for either diagnostic or therapeutic applications, or for theranostics, which is a
combination of both of these [25].
2.1.1 Nanoparticles in Therapeutics
One major application for nanoparticles in therapeutics is as a drug carrier, pro-
tecting the drug from premature activation during transport to the diseased site [6].
The nanoparticle may be functionalized to bind specifically to certain cells, e.g.
tumorous cells, increasing the dose arriving at the desired location and reducing
the dose to healthy parts of the body. In cancer therapy, this reduces side effects
of common chemotherapeutics, permitting use of even higher doses to increase the
effectiveness of the therapy. A controlled release of the drug from the nanoparticle
may be achieved by controlling the material composition of the nanoparticle and
the way by which the drug is associated with the carrier [6]. Some of the most
common types of nanoparticles for medical applications are described next and
shown in Figure 1.
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Figure 1: Different types of nanoparticles [10].
Polymeric Nanoparticles The drug can be either physically entrapped or co-
valently bound to a polymer matrix, depending on the method of preparation [10].
Polymeric nanoparticles (Figure 1A) usually have the structure of capsules or
spheres [17] and can be made from naturally occurring polymers such as albumin,
chitosan and heparin [10] or from synthetic polymers such as polyethylene glycol
(PEG), poly-L-glutamic acid (PGA) or poly(butyl cyano acrylate) (PBCA).
Polymeric Micelles Polymeric micelles (Figure 1B) are spherical or globular
core/shell structures formed by (self-)assembly of amphiphilic block copolymers in
aqueous media [10, 17]. The micelle usually has a hydrophilic shell region which
stabilizes a hydrophobic core region that serves as a reservoir for hydrophobic
drugs [10]. Hydrophilic drugs can be loaded if the interior of the micelle is hy-
drophilic. The drug can be loaded either by physical encapsulation or by chemical
covalent attachment, as for polymeric nanoparticles [10].
Dendrimers Dendrimers (Figure 1C) are three-dimensional branched polymeric
structures, composed of multiple highly branched monomers that emerge radially
from a multifunctional central core molecule [10, 17]. Some properties that make
them attractive for drug delivery are their monodispersity and water solubility,
and the interior dendritic channels where drugs may be loaded [10, 17]. Drug
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molecules may also be attached to the dendrimer surface [17]. Dendrimers can
host both hydrophobic and hydrophilic molecules [17].
Liposomes Liposomes (Figure 1D) are self-assembling closed spherical struc-
tures composed of lipid bilayers surrounding a central aqueous space [10]. They
are classified as either unilamellar or multilamellar according to the number of
lipid bilayers [17]. Unilamellar liposomes entrap hydrophilic drugs, whereas multi-
lamellar liposomes can load hydrophobic drugs [17].
Viral-based Nanoparticles Viral-based nanoparticles (Figure 1E) are well-
characterized, monodisperse and highly symmetrical structures [50]. They are
based on the structures of naturally occurring viruses. The internal cavity of
the structure can be filled with e.g. drugs or other nanoparticles, and the external
surface can, as for the other classes of nanoparticles, be functionalized for targeting
purposes [50]. Besides this artificial targeting, some viruses have a natural affinity
for certain receptors that are often up-regulated on tumor cells [10].
Carbon Nanotubes Carbon nanotubes (Figure 1F) are ellipsoid carbon tubes
composed of benzene rings [10, 17]. There are some health concerns and toxicity
problems related to carbon nanotubes due to their complete insolubility in all
solvents [10]. However, the surface can be chemically modified to render them
water soluble, and they may be functionalized so that they can be linked to active
molecules [10] such as drugs or targeting ligands. Atoms may also be trapped in
the interior of the tubes [17].
2.1.2 Nanoparticle Characeristics Affecting Drug Delivery
The main motivation for loading drugs in nanoparticles, besides protecting them
from premature activation, is to passively target the drugs to tumor tissue by uti-
lizing the enhanced permeability and retention (EPR) effect (see Section 2.2.5). In
order to do this, the nanoparticles must remain in the blood stream for a consider-
able time without being eliminated by the reticuloendothelial system (RES) [10].
The mean half-life of conventional nanoparticles with a non-modified surface af-
ter intravenous administration is 3-5 minutes [6]. One of the advantages of using
nanoparticles as drug carriers is that the size of the particle and the surface char-
acteristics can be adjusted to considerably increase the circulation time of the drug
in the body [10].
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Size Nanoparticles used in drug delivery systems should have a size large enough
to prevent rapid leakage into blood capillaries, but small enough to escape capture
by fixed macrophages in the RES [10]. To increase the circulation time in the body,
the size of the nanoparticle must be above the renal clearance threshold [30]. The
renal clearance is inversely proportional to the size of the particle, and hence
circulation time increases as the size of the particle increases [24].
Surface Characteristics and PEGylation Clearance of nanoparticles from
the body by the RES depends not only on the size of the particles, but also
on the surface characteristics [24]. To escape macrophage capture nanoparticles
should ideally have a hydrophilic surface [10]. This can be achieved either by using
polymeric micelles with a hydrophilic shell as a nanocarrier, or by coating the
surface of other nanoparticles with a hydrophilic copolymer [10]. The most common
approach is to coat the nanoparticle surface with the hydrophilic polymer PEG,
typically referred to as PEGylation [24].
2.1.3 Nanoparticles in Diagnostics
The contrast of images obtained using common diagnostic imaging modalities,
such as MRI, X-ray and ultrasound, can be enhanced by using contrast agents
while imaging. Many of the advantages of using nanoparticles for therapeutic
purposes are also advantages of using nanoparticles as contrast enhancers. When
using nanoparticles as contrast agents, longer imaging duration is possible due
to the long circulation time of nanoparticles in the body [16]. In addition, the
nanoparticles may be targeted, e.g. to specific organs, for more specific imaging [3].
Ultrasound is a non-invasive, low-cost diagnostic imaging tool. Nanoparticle con-
trast enhancers enable ultrasonic imaging in situations where it was previously
impossible due to poor contrast. Microbubbles are a type of particles that are
currently used as contrast agents for ultrasonic imaging. Reflection of sound is
increased by creation of an acoustic impedance mismatch between fluids and tis-
sues [49]. Microbubbles do however also have potential applications in therapeu-
tics [49], and an advantage of using microbubbles in medicine is that the same
particle can be used both for therapy and diagnostics. The topics of ultrasound
and microbubbles are further reviewed in Section 2.5.
2.2 Cancer Tissue
In healthy tissue there is a balance between cell division and cell differentiation,
ensuring that the number of dividing cells does not increase [2]. A disruption of
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this balance results in an accumulation of dividing cells and a mass of growing
tissue termed a tumor. Tumor growth is quick if the cells are dividing rapidly and
slower if the cells are dividing more slowly, but since cells are produced in greater
numbers than needed, the tumor will continue to grow regardless of the speed of
cell division [2]. Tumors are classified as benign if they grow in a confined local
area, and malignant if they can invade surrounding tissues, enter the bloodstream
and spread to distant locations [2]. Malignant tumors are termed cancer, and the
ability of cancer to grow in an uncontrolled manner and spread to distant parts of
the body makes it a potentially life-threatening disease [2].
2.2.1 Angiogenesis
Mammalian cells are located within 100 to 200 µm of blood vessels, which is the
diffusion limit for oxygen, to assure that they receive the oxygen and nutrients
required for their survival [7]. Hence, for tumors to be able to grow beyond a few
millimeters in diameter, angiogenesis, that is, the growth of new blood vessels, is
required [2]. To trigger angiogenesis, tumors increase the production of angiogen-
esis activators such as vascular endothelial growth factor (VEGF) and fibroblast
growth factor (FGF), and simultaneously decrease the production of angiogenesis
inhibitors [2].
2.2.2 Metastasis
The cancer cells are able to spread throughout the body, or metastasize, once
angiogenesis has been triggered at the tumor site [2]. Following angiogenesis, three
other steps are also neccessary in order for metastasis to occur [2]. The first step
involves cancer cells gaining access to the blood stream by invading surrounding
tissues and penetrating the walls of lymphatic and blood vessels. Once they have
accessed the blood stream, the cancer cells are transported by the circulatory
system throughout the body. Lastly, the cancer cells leave the blood stream and
establish new metastatic tumors in particular organs [2]. Metastasis can not occur
if one of these steps is prevented [2].
2.2.3 Tumor Vasculature
The movement of compounds through the vasculature is affected by vascular mor-
phology [24]. Blood vessels in tumors differ greatly from those in normal tissues,
both on a macroscopic and on a microscopic level.
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On the macroscopic level, tumor vessels lack hierarchic branching from larger ves-
sels into successively smaller vessels that feed a capillary bed [24] (Figure 2). They
are heterogeneously distributed in the tumor tissue, dilated and tortuous, and some
spaces are even left avascular [24]. Microscopically, the vessel wall structure is ab-
normal and irregular. Compared to vessel walls in normal tissues, interendothelial
junctions are wider, the thickness of the basement membrane is abnormal, pores are
considerably larger and there are large numbers of fenestrae and transendothelial
channels [24]. The irregularity of the vessel walls render them leaky and hyperper-
meable in some places, while not in others [24].
Figure 2: Differences between blood vessels in normal (A) and cancerous (B) tissue.
Tumor blood vessels are heterogeneous, dilated and tortuous, and lack hierarchic
branching. Source: [22].
The large number of proliferating cells in the tumor also adds to the irregularity
and spatial heterogeneity of the vessels by compressing them, sometimes to such
an extent that the vessels collapse [24]. As a result, some regions can be left
unperfused. This may lead to hypoxia and acidosis, causing resistance to several
cytotoxic drugs and compromising the cytotoxic functions of immune cells [24].
2.2.4 Lymphatic Network
Proliferating tumor cells compress not only blood vessels, but also lymphatic ves-
sels [24, 40]. The interstitial fluid balance is normally maintained by the lymphatic
network, which drains excess fluid from healthy tissue. When lymphatic vessels in
the tumor tissue collapse as a result of the compression, the fluid drainage becomes
inefficient [24]. This tends to happen especially in the center of the tumor, leaving
functional lymphatic vessels only in the tumor periphery [24]. Coupled with the
fluid leakage from tumor blood vessels, this inefficient fluid drainage contributes
to interstital hypertension [24].
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2.2.5 Enhanced Permeability and Retention Effect
The EPR effect is a phenomenon that results in a preferential accumulation of
macromolecules in tumor tissue over normal tissue. The leakiness of the tumor
blood vessels means that blood plasma components end up in the tumor inter-
stitium, and the poor lymphatic clearance means that macromolecules are not
removed from the tissue [20]. As the extravasation from tumor blood vessels con-
tinues, macromolecules accumulate.
Figure 3: Low molecular weight (Mw) drugs are able to diffuse freely across the
tumor vessel walls, owing to their small size. As the blood plasma drug concen-
tration is reduced over time, the effective concentration of drug in the tumor is
also diminished. However, the large size of high Mw drugs means that they are
not able to diffuse back into the blood stream, and hence macromolecular drugs
accumulate in the tumor tissue over time. Source: [20].
Low-molecular-weight drugs, such as antibiotics and many chemotherapeutic agents,
reach both normal and tumor tissues by free diffusion-dependent equilibrium [30],
and are returned to the circulating blood by diffusion [29] and cleared by the renal
system [20]. Hence, the EPR effect does not apply, and they do not accumulate,
even in tumor tissue. This is the background for using macromolecular drugs, e.g.
loading conventional chemotherapeutics into nanoparticle carriers, instead of the
low-molecular-weight drugs that are normally used to treat cancer today. Since the
EPR effect does apply for macromolecules, it can be utilized to selectively target
macromolecular drugs to solid tumors [33]. This is becoming a gold standard for
the design of new anticancer agents [33].
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2.3 Barriers for Drug Delivery
Once a drug has been administered, it needs to be transported from the site of
injection to the part of the body where it’s supposed to excert its effect. Drug deliv-
ery to the intended site is dependent on three transport steps. These are vascular
transport, transport via blood vessels; transvascular transport, transport across
the vessel wall; and interstitial transport, transport through the tumor tissue to-
ward the target cells [9] (see Figure 4). In normal tissues, these transport steps are
highly efficient, as they developed for effective oxygen and nutrient transport [9].
However, the abnormal physiology of tumor tissue, described in Section 2.2, gives
rise to transport barriers that limit drug delivery to tumors [9].
Figure 4: Drugs must travel through the blood stream (vascular transport), across
the vessel wall (transvascular transport) and through the interstitium (interstitial
transport) to reach the tumor cells. Source: [21].
2.3.1 Abnormalities Contributing to Transport Barriers
There are four major abnormalities of tumor tissue that limit drug delivery [9].
Each of these can limit multiple transport processes [9]. The first three abnormal-
ities have previously been described in Section 2.2.
Accumulated Solid Stress The large number of proliferating cells, together
with an overproduction of interstitial matrix molecules, in tumor tissue leads to
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an accumulation of solid stress. This is the first abnormality of tumor tissue that
limits drug delivery. The solid stress compresses blood vessels, which leads to
reduced perfusion to many regions of the tumor [9]. The poor perfusion means
that drug distribution is limited [9].
Immature Tumor Vasculature Secondly, the immaturity of the tumor vascu-
lature also limits drug delivery. The high tortuosity of tumor blood vessels leads
to an increased geometric resistance, which slows blood flow [9]. In addition, the
hyperpermeability of the blood vessels means that the viscosity of the blood in-
creases due to fluid loss, which further slows blood flow [9]. This combination of
effects means that blood flow through tumor tissue is very slow and heterogeneous
compared to normal tissue, and is a major barrier to vascular transport and hence
drug delivery [9].
Elevated Interstitial Fluid Pressure Thirdly, the compression of lymphatic
vessels combined with the leakiness of the blood vessels means that fluid accu-
mulates in the interstitial compartment of the tumor. This accumulation of fluid
leads to an elevated interstitial fluid pressure (IFP) inside the tumor. The IFP
becomes almost equal to the microvascular pressure [4], resulting in a lack of inter-
stitial fluid pressure gradient, and hence the driving force for convective interstitial
transport is diminished [9]. Diffusion is left as the main transport mechanism for
drugs in the bulk of the tumor, resulting in short penetration distances and poor
drug distribution [9].
Dense Interstitial Structure The last abnormality of some types of tumor tis-
sue that reduces drug delivery is the dense interstital structure of the tumor [9]. The
extracellular matrix (ECM) of animal cells consists of three classes of molecules [2].
The first class is structural proteins, and the most important of these are colla-
gens, accounting for much of the strength of the ECM, and elastins, providing
the elasticity and flexibility [2]. The structural proteins are embedded in a matrix
consisting of proteoglycans, which is the second group of molecules in the ECM [2].
Proteoglycans are glycoproteins in which a large number of glycosaminoglycans,
a type of large carbohydrates, are attached to a single protein molecule [2]. The
last group of ECM molecules are the adhesive glycoproteins, of which the two
most common are fibronectins and laminins [2]. Adhesive glycoproteins bind pro-
teoglycans and collagen molecules to each other and to receptors on the membrane
surface [2].
The high cellularity of tumors and the overproduction of interstitial matrix molecules
can cause the matrix to be compressed into a tortuous and dense network [9], de-
pending on tumor type. Some tumor types contain a lot of enzymes that break
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down the ECM, creating a large interstitial space [23]. For tumors with a dense in-
terstitium, the interstitial density generally increases toward the tumor center [31].
Diffusion is slow as the matrix is dense, and diffusion path lengths from blood ves-
sels to target cells are extremely long due to the tortuosity of the matrix [9].
This greatly limits drug delivery. As many drugs bind to matrix and cellular
components, interstitial transport rates become even lower, further limiting drug
delivery [9].
2.3.2 Diffusion as the Main Transport Mechanism
Both transvascular and interstitial transport normally occur through a combina-
tion of diffusion and convection [9] (see Figure 5). Diffusion is a much slower
process than convection, particularly for large particles [24].
Figure 5: Transport steps. Both transvascular and interstitial transport normally
occur through a combination of diffusion and convection. Diffusion is a much
slower process than convection. Source: [9].
As mentioned in Section 2.3.1, a direct consequence of the lack of IFP gradient
in tumors is that diffusion is left as the main transport mechanism [24], both for
transvascular and interstitial transport. The reduced transvascular transport lim-
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its drug delivery to tumor tissue. It is even possible for the IFP to exceed the
microvascular fluid pressure and hence cause intravasation of material back into
the blood supply [24]. For interstitial transport, the diffusion rate in the interstitial
matrix depends on the size and charge of the particle, as well as psysicochemical
properties of the matrix [24]. Diffusion of small-molecular drugs such as chemother-
apeutics is fairly rapid, but the diffusion of comparably large nanoparticles is con-
siderably hindered by interactions with the interstitial matrix [24]. In addition,
electrostatic forces develop between charged particles and charged components of
the interstitial matrix [24]. This can further hinder diffusion.
2.3.3 Non-uniform Delivery
As the pores in tumor blood vessels are larger than in normal blood vessels, drug-
loaded nanoparticles are able to extravasate into the tumor interstitium [24]. How-
ever, the heterogeneous distribution of pore sizes means that the extravasation and
delivery of drugs is non-uniform [24].
Once the particles have reached the interstitium, uniform distribution in tumor
tissue is hindered by the heterogeneous distribution of interstitial matrix compo-
nents [24]. The matrix can be separated into a viscous, high-collagen phase and an
aqueous, low-collagen phase [24]. The viscous phase greatly hinders particle move-
ment, while the diffusivity in the aqueous phase is similar to that in water [24].
Hence, the heterogeneous distribution of phases leads to non-uniform distribution
in the tumor.
2.4 Uptake Mechanisms in Cells
In order to exert its effect, a drug that has an intracellular target must be inter-
nalized into the cells once it has reached its site. There are several mechanisms by
which material can reach the interior of the cell.
2.4.1 Simple Diffusion
Simple diffusion, the unassisted net movement of a solute along its concentra-
tion gradient, is the most straightforward way for a solute to cross the cell mem-
brane [2]. It is a relevant means of transport only for some small, relatively non-
polar molecules such as oxygen, carbon dioxide, water and ethanol, owing to the
hydrophobic interior of cell membranes [2]. The movement of water across a selec-
tively permeable membrane from regions of lower solute concentration to regions
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of higher solute concentration is termed osmosis [2]. Diffusion is always movement
toward equilibrium, and hence a spontaneous process [2]. There are three main
factors affecting diffusion of solutes: size, polarity and charge.
Size Lipid bilayers are generally more permeable to molecules the smaller they
are [2]. Water, oxygen and carbon dioxide are the smallest molecules relevant to
cell function, but even molecules as small as these can not diffuse freely across the
membrane; for example, compared to free diffusion in the absence of a membrane,
water molecules diffuse 10 000 times slower across a bilayer [2]. Molecules with
molecular weights (Mw) of above about 100 Da, such as glucose (Mw 180 Da), are
unable to cross the cell membrane by simple diffusion [2]).
Polarity Since nonpolar, or hydrophobic, molecules dissolve more readily in the
hydrophobic phase of the lipid bilayer than do polar molecules, the cell membrane
is more permeable to nonpolar molecules compared to polar molecules of similar
size [2]).
Charge Polar molecules in general, and ions in particular, have a strong associ-
ation with water molecules, forming a shell of hydration [2]. The water molecules
must be removed in order for such solutes to move into the membrane [2]. As an
input of energy is required to strip off the water molecules, the formation of shells
of hydration hinders ion transport across membranes [2].
2.4.2 Facilitated Diffusion and Active Transport
Although a few types of molecules are able to cross the membrane at reasonable
rates by simple diffusion, most are dependent on an alternative means of transport
as they are either too large or too polar [2]. Transport proteins in the cell membrane
mediate the movement of such molecules across the membrane [2]. Most of them
are highly specific [2]. If the solute moves along its gradient, the process requires
no input of energy and is termed facilitated diffusion [2]. If, however, the solute
needs to be moved against its gradient, additional energy is required. This process
is called active transport. Transport proteins involved in active transport couple
an energy demanding process (the movement of a solute against its gradient) to
an energy-yielding one (usually ATP hydrolysis) [2].
18
2.4.3 Endocytosis
Material that can not cross the plasma membrane by either of the transport mech-
anisms specified above, may be internalized by a process termed endocytosis. Once
endocytosed, the material is separated from the cytosol by a portion of the plasma
membrane, and hence is not really ”inside” the cell.
During endocytosis, the plasma membrane invaginates and then pinches off to
form an endocytic vesicle [2] (Figure 6). Early endosomes are formed as endocytic
vesicles coalesce with vesicles from the trans-Golgi network containing lysosomal
enzymes [2]. The early endosome matures over time to form a late endosome.
During this process the pH of the lumen drops and the organelle can no longer
fuse with endocytic vesicles [2]. In a final step the pH of the lumen is further
lowered to activate acid hydrolases. This is accomplished in one of two ways. The
late endosome is either transformed into a lysosome when ATP-dependent proton
pumps lower the pH of the lumen, or the late endosome fuses with an already
existing lysosome and transfers its content to its acidic lumen [2]. The material
ingested during endocytosis is digested in lysosomes.
Figure 6: Endocytosis. The plasma membrane invaginates and then pinches off to
form an endocytic vesicle. Source: [34].
Receptor-Mediated Endocytosis Receptor-mediated endocytosis is a specific
internalization mechanism where receptors found on the plasma membrane are
used to aquire material from the outside of the cell [2]. It is dependent on the
protein clathrin and is hence also referred to as clathrin-dependent endocytosis. If
nanoparticles are functionalized with the right ligands, receptor-mediated endocy-
tosis may be the mechanism of their internalization.
The process begins with the binding of specific molecules called ligands to their
receptors on the cell surface. Receptor-ligand complexes then diffuse in the plasma
membrane and accumulate in special membrane regions called coated pits [2]. The
receptor-ligand complex accumulation triggers accumulation of additional proteins,
among them clathrin, that are required for membrane curvature and invagina-
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tion [2]. The membrane continues to invaginate until the pit pinches off, forming
a coated vesicle, at which point the clathrin coat is released, leaving an uncoated
vesicle [2]. The uncoated vesicle is then free to fuse with an early endosome.
Clathrin-Independent Endocytosis Apart from the clathrin-dependent type
of endocytosis, there are also other types of endocytosis that are not dependent on
clathrin. Of these clathrin-independent pathways, caveolin-dependent endocytosis
and macropinocytosis are the most important.
Caveolin-dependent endocytosis is endocytosis via caveolae, which are flask-shaped
invaginations found in the plasma membrane of many cell types [41]. Caveolins are
essential for the formation and stability of caveolae [41]. When material is taken
up by this pathway, the caveolae pinch off and become caveolin-coated endocytic
vesicles [41]. Once internalized, caveolar vesicles enter sorting compartments called
caveosomes, which are distinct from endosomes, and are then distributed mainly
to the ER and Golgi complex [41].
Macropinocytosis is a form of endocytosis where single surface lamellipodia bend,
giving rise to curved ruﬄes, and seal back onto the plasma membrane, forming
macropinosomes [13]. In this way the cell internalizes large volumes of extracellular
fluid, as well as solid material present in the extracellular fluid [13].
2.5 Overcoming the Barriers
To enhance drug delivery, the barriers of drug delivery must be overcome. This is
normally done by some physical means. One way is to use ultrasound. Pressure
waves produced by ultrasound can be concentrated through cavitating gas bodies,
such as microbubbles (see Section 2.5.2), to produce forces that permeabilise cell
membranes and disrupt the drug carrying vesicles [42]. In this way they assist
in overcoming the barriers for drug delivery, and the presence of microbubbles
enhances ultrasonic delivery [42].
2.5.1 Ultrasound
Ultrasound is the transmission of pressure waves at frequencies above what the
human ear can detect. Ultrasonic waves are the actual movement of molecules
in the medium as the pressure changes; the medium is compressed at high pres-
sure and expanded at low pressure, and hence ultrasound can act physically on
biomolecules and cells [42]. The waves are absorbed relatively little by water, flesh
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and other tissues, and this safe, non-invasive and painless technique can be used
to transmit energy into the body at precise locations [42].
Ultrasonic treatment can be used to enhance drug delivery by several mechanisms.
The simplest of these is the oscillation of the insonated fluid, which increases the
effective diffusivity of molecules [42]. The transport of any drug will be augmented
by the oscillatory motion of the fluid. Other than this, there are three main effects
of ultrasound that are taken advantage of to enhance drug delivery. They are
thermic effects, cavitation and radiation force.
Thermic Effects Ultrasound can be used to induce hyperthermia by focusing
the beam down to a small size on the targeted tissue. Acoustic energy is removed
from the ultrasound wave and absorbed by the tissue [19]. The power/area be-
comes very large and the tissue absorbs thermal energy, resulting in heating of the
tissue [42]. Hyperthermia can be used either for direct treatment of small and lo-
calized tumors by high-intensity ultrasound [8, 35], or to enhance radiation therapy
and chemotherapy by low-intensity ultrasound [35, 18]. In drug delivery, hyper-
thermia works by heating the drugs, drug carriers and/or the tissues receiving the
drugs [42].
Cavitation The term cavitation refers to the creation, oscillation, growth and
collapse of gas bubbles within a medium exposed to an ultrasonic field [19, 1].
The acoustic pressure within an ultrasonic field acts on gas bubbles to make the
bubble radius vary [19]. The bubble expands at low pressure and contracts at high
pressure [42], behaving as an oscillator with a natural resonant frequency [19]).
If the oscillation is stable, it is referred to as ”stable” cavitation (Figure 7A).
During stable cavitation, a circulating fluid flow called microstreaming is created
around the bubble [37]. In addition, a phenomenon called acoustic pressure re-
sults in bodies more dense than the suspending fluid being pushed toward the
bubble [36]. Most drug carriers containing drugs will be convected toward the
bubble and into the microstreaming field, since they are usually more dense than
water [42]. The velocities and shear rates of the microstreaming eddies are propor-
tional to the amplitude of oscillation, and near the bubble surface they are high
enough to cause stress to cells and vesicles [42]. At high amplitudes, the associated
shear forces are capable of inducing hemolysis [45] and disrupting drug carriers
such as liposomes [32], enhancing dispersive drug transport [42].
As the ultrasonic intensity increases, the amplitude of gas bubble oscillation also
increases. At some point, the fluid wall moving inward has sufficient inertia that it
does not reverse direction when the acoustic pressure reverses. Instead, it contin-
ues to compress the gas in the bubble to a very small volume, creating extremely
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high pressures and temperatures [5], and the bubble collapses. This type of cavita-
tion is called collapse cavitation. The collapse produces very high shear stresses in
the collapse region, a shock wave (Figure 7B), and free radicals resulting from the
high temperatures, all three of which can be detrimental to cells or vesicles [42].
The collapsed bubble often fragments into smaller bubbles serving as cavitation
nuclei, which grow in size and eventually collapse again [5]. If the collapse is near
a solid surface, a liquid jet is ejected toward the surface at sonic speed [5], capa-
ble of piercing e.g. blood vessel walls, skin, large cells or semi-rigid vesicles [42]
(Figure 7C).
Figure 7: Stable cavitation of a gas bubble (A), collapse cavitation emitting a
shock wave (B), and collapse cavitation near a surface, with ejection of liquid jet
(C). Source: [42].
The occurrence of collapse cavitation for a particular spherical bubble nucleus in
a given liquid depends on the acoustic pressure amplitude, the acoustic frequency
and the bubble radius [19]. An expression called the mechanical index (MI) can
be considered to be an indicator of the likelihood of collapse cavitation [19]. It is
defined as
MI =
pr√
f
, (1)
where pr is the peak rarefactional pressure in MPa and f is the frequency in
MHz [19]. If the threshold MI of 0.7 is not reached, the probability of collapse
cavitation is considered negligible [19]. The maximum allowed MI value that is
allowed for diagnostic machines in the US is 1.9 [19].
Radiation Pressure Radiation pressure is a secondary physical effect that can
be generated by an ultrasonic field [19]. For a continuous acoustic wave it is a
steady, small force that acts in the direction of propagation of the wave [19].
Radiation pressure leads to a force on particles in the ultrasonic field, which can
result in particle movement for small particles [19].
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2.5.2 Microbubble-Enhanced Ultrasound
Microbubbles used for ultrasound contrast enhancement are usually 1-4 µm in di-
ameter, and are hence restricted to the vascular compartment [26]. They can be
gas bubbles stabilized by surfactants, gas bubbles with a shell made from phos-
pholipids, proteins or polymers [26], or they can even be made from a shell of
nanoparticles.
The effect of using microbubbles combined with ultrasound in drug delivery has
previously been proven by others. For example, Kinoshita et al. [27] were able
to deliver Herceptin to the central nervous system of mice by using microbubbles
combined with ultrasound to open the blood-brain barrier. Lawrie et al. [28] re-
ported that ultrasound exposure in the presence of microbubble contrast agents
enhanced transgene expression in vitro approximately 300-fold after naked DNA
transfections, compared to naked plasmid DNA alone. Rapoport et al. [44] showed
that administration of microbubble-encapsulated Doxorubicin combined with ul-
trasound treatment reduced tumor growth in mice. Escoffre et al. [12] observed a
decrease in tumor growth and perfusion and an increase in tumor necrosis in nude
mice treated with Irinotecan with microbubble-assisted ultrasound. Todorova et
al. [48] reported significant tumor growth inhibition relative to control tumors for
ultrasound-stimulated microbubble (USMB) treatment only, and an even stronger
growth inhibition for USMB in combination with metronomic Cyclophosphamide.
2.6 Confocal Laser Scanning Microscopy
In biomedical sciences, confocal laser scanning microscopy (CLSM) is used for
imaging fluorescently labeled tissues, either fixed or living [39]. The main advantage
of confocal imaging lies in the ability of the microscope to eliminate fluorescence
from areas of the specimen that are outside a focal plane. The spatial filtering
characteristic of the confocal approach is achieved by placing a variable pinhole
aperture in the image plane, in front of the detector [46] (7 in Figure 8). The
pinhole assures that only light emanating from the focal plane is passed through
to the detector [46]. CLSM offers a slight increase in resolution compared to a con-
ventional wide-field light microscope, and it has bridged the gap between the com-
monly used techniques light microscopy and transmission electron microscopy [39].
CLSM produces an optical section of the specimen, and is hence a non-invasive
method using light rather than physical means to section the specimen [39]. Thus,
the confocal method allows for imaging of living specimens [39].
23
Figure 8: Confocal Laser Scanning Microscope. Source: Zeiss.
The illumination of the specimen in a CLSM is achieved by scanning a laser beam
across the specimen in a raster pattern. The laser beam is focused to a spot by an
objective lens, and scanning mirrors are used to control the position of the laser
spot [2]. As the laser beam is scanned across the specimen, fluorescent light is emit-
ted from fluorophores in the specimen. The fluorescence is red shifted compared to
the laser as the wavelength is slightly longer. The emitted fluorescence is collected
by the objective lens and returned along the path of the original incoming light [2].
A dichroic mirror is used to separate the incoming light from the fluorescence, as
it transmits light with the wavelength of the fluorescence and reflects light with
the wavelength of the laser beam [2]. The transmitted fluorescence then passes
through the pinhole aperture, and light from the focal plane reaches the detector.
2.6.1 Spectral Imaging and Linear Unmixing
If the specimen is subject to artefacts arising from autofluorescence, spectral imag-
ing combined with linear unmixing can be used to separate mixed fluorescent sig-
nals [11].
Spectral imaging merges spectroscopy and imaging to provide a complete spectrum
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of the specimen at every pixel location [11]. Hence, a spectral image stack, often
referred to as a lambda stack, can be considered as either a collection of images,
each measured at a specific wavelength, or as a collection of different wavelengths
at each pixel location [11].
Lambda stacks are virtually impossible to analyze by visual inspection, and require
dedicated software for interpretation and presentation of the results [11]. Regard-
less of the spectral overlap with other probes, each probe has a unique spectral
signature, or an emission fingerprint, that can be determined by linear unmixing
of lambda stacks [11]. The result is conversion of a lambda stack into individual
images representing the signal profile for each fluorescent probe [11].
Spectral imaging and linear unmixing can be used to reduce or completely elimi-
nate unwanted autofluorescence from images [11]. This is accomplished by treating
the autofluorescence as a separate fluorophore with a distinct emission finger-
print [11].
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3 Materials and Methods
3.1 Experimental
3.1.1 Gas Bubbles and Nanoparticles
The gas bubbles that were administered to the mice are made from a shell of the
poly(butyl cyano acrylate) (PBCA) nanoparticles YM-59. The bubbles are made
with 1 % bovine serum albumin for stabilization. The size of the bubbles is 1-6
µm.
YM-59 are PBCA nanoparticles with encapsulated nile red and 1,1’-dioctadecyl-
3,3,3’,3’-tetramethylindotricarbocyanine iodine (DiR), sodium dodecyl sulfate (SDS)
as surfactant and Jeffamin M-1000 as PEG. The polymer is crossbound. The size
is 194 nm and the polydispersity index is 0.07. The particles have a low PEG
density.
Both the YM-59 nanoparticles and the gas bubbles stabilized by the nanoparticles
were made by SINTEF.
3.1.2 Ultrasound Exposure
PC-3 prostate adenocarcinoma cells (American Type Culture Collection, Manas-
sas, VA, USA) were injected subcutaneously in the hind leg of female Balb/c nude
mice (C.Cg/AnNTac-Foxn1nu NE9, Taconic, Lille Skensved, Denmark) as a 50
µL suspension containing 3×106 cells. After 3-6 weeks of tumor growth, when
the tumor diameter had reached between 5 and 10 mm, 200 µL of a solution
containing gas bubbles stabilized by YM-59 was administered intravenously. Fol-
lowing administration, the mice were divided into four treatment groups, three of
which received different ultrasound treatments that are presented in Table 1. Ul-
trasound treatment begun about 30 seconds after administration. The last group
was a negative control and received only nanoparticle stabilized gas bubbles, but
no ultrasound treatment. In addition, one mouse did not receive ultrasound or
gas bubbles. 100 µL fluorescein-labeled Lycopersicon esculentum (Tomato) lectin
(FITC-lectin) (Vector Laboratories) diluted to 1 mg/mL with 0,9 % NaCl was
injected intravenously to label blood vessels. FITC-lectin was allowed to circulate
for 5 minutes before the mice were euthanized. The tumor was then excised and
embedded in OTC Tissue Tec (Sakura, Alphen aan den Rijn, The Netherlands)
and frozen in liquid N2.
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Table 1: The four different ultrasound treatments that the mice were exposed to.
f is the frequency of the ultrasound and pr is the acoustic pressure. Mechanical
index MI was calculated from (1).
f pr MI Pulse duration PRF Insonation time
US 1 1 MHz -0.1 MPa 0.1 10 cycles 3000 2 min
US 2 1 MHz -0.4 MPa 0.4 10 cycles 3000 2 min
US 3 1 MHz -0.4 MPa 0.4 10 cycles 3000 2 min
and 5 MHz -1.6 MPa 2.24 20 cycles 1000 10 in each spot
The difference between US 1 and US 2 was the MI. The purpose of US 1 was to
make the bubbles oscillate without collapsing, while the purpose of US 2 was to
induce bubble collapse to free the nanoparticles, which hopefully then would cross
the vessel wall. The purpose of US 3 was to see if an effect of radiation pressure
could be observed. The first part of the ultrasound treatment in US 3 was the same
as for US 2, hence the goal was to get the nanoparticles across the vessel wall. The
second part of US 3 generated a positive pressure of 7.1 MPa, and was designed
to increase the probability of achieving a radiation force to push the nanoparticles
further into the tumor tissue.
3.1.3 Tumor Sections
The procedure for sectioning of the tumor is shown in Figure 9. The top 500 µm
of the tumor was removed to make sure the sections were from inside the tumor.
25 frozen sections were then made from each tumor. Every section has a thickness
of 25 µm. Five sections were made from five different positions in the tumor,
with 250 µm between each position, meaning that sections 1-5 are from the most
superficial position, section 6-10 from the next position, etc. One section out of
the five from each position was randomly chosen and imaged, five sections in total
from each tumor. The sections were mounted to objective glass slides and stored
in a freezer at -88◦C.
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Figure 9: Average total fluorescence for one section, averaged over each treatment
group.How the sections are made.
3.1.4 Section Preparation
For microscopic examination, the sections were removed from the freezer and 40
µL of Vectashield mounting medium (Vector Laboratories, Burlingame, CA, USA)
was carefully applied on top of the tumor sections on the glass slides, making sure
no air bubbles were introduced. A cover glass was then placed on top of the
objective glass slide with the Vectashield drop. Again, care was taken to avoid air
bubbles. Once the cover glass was in place, the edges were sealed with nail polish,
and the sections were ready for the microscope.
3.1.5 Microscopy
A Zeiss LSM510 confocal microscope (Jena, Germany) was used to image the
sections. Nile red was excited using the 543-nm He/Ne laser line. FITC-lectin
was excited using the 488-nm Ar laser line. Tile scan images were taken using a
20x/0.5 objective. To obtain tile scans, the sections were imaged from periphery
to periphery through the center of the tumor using the tile scan function of the
microscope. Each single image had a resolution of 512×512 pixels, and the number
of images in the tile scan depended on the size of the tumor section. For tumors
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where the tumor diameter through the center exceeded the maximum size of a tile
scan, tile scans were taken closer to the periphery where the diameter was smaller.
Single images were taken using a 63x/1.4 oil objective. All images were aquired
using the same microscopy settings, to allow for quantitative analysis. All images,
both tile scans and single images, were taken in channel mode and in lambda mode.
A mercury lamp was used when looking through the oculars during positioning
before images were taken.
3.2 Analysis
The microscope images were analyzed using the Zeiss LSM510 software.
3.2.1 Quantitative Analysis
Channel mode and lambda mode images were taken to allow for linear unmixing to
separate autofluorescence from nile red fluorescence. The Zeiss LSM510 software
was used to perform linear unmixing on the lambda mode images. The spectra
used for unmixing are shown in Figure 10.
(a) Free nile red (b) Nile red bound to fat (c) Autofluorescence
Figure 10: Spectra used for linear unmixing (20x/0.5 objective).
Following unmixing, a matlab routine was run on the images to quantitatively
analyze the fluorescence throughout the tile scans. The routine divides the tile scan
into segments of a chosen size, and counts the number of pixels with fluorescence
intensity higher than a pre-chosen threshold value. The threshold value was set
to 0.22. A result file was produced containing the calculated fluorescent area in
each segment, and the mean fluorescence of the segment. From this, the total
fluorescence of each segment was calculated using of the formula
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TotFl = MeanInt×Area, (2)
where TotFl is the total fluorescence of each segment, MeanInt is the mean fluores-
cence of the segment, and Area is the calculated fluorescent area of the segment.
The estimated total fluorescence from one section was calculated by adding the
total fluorescence from all segments of that section. The average total fluorescence
of all five section from each mouse, and the standard deviation, was calculated and
plotted for each treatment group. In addition, the average total fluorescence from
all mice within each treatment group, and the standard deviation, was calculated
and plotted.
The matlab routine was also used to obtain line plots of fluorescence versus relative
position in the tile scan. Each tumor section was divided into 10 segments, and
the total fluorescence was calculated for each of these 10 segments. In this way, 10
measurement points were obtained. For each measurement point, the average total
fluorescence of that relative position was found for each mouse. From this again,
the average for each treatment group was found.The average total fluorescence from
each segment was plotted against relative position from 0-1 as a line plot. Five
different figures were produced: One for each of the four treatment groups, each
containing one graph per mouse, and one for all treatments combined, containing
one graph per treatment group. To produce the plots, the average of the total
fluorescence in each segment (position) of all sections from one mouse was found.
For the plot comparing treatment groups, the average of the total fluorescence in
each position from all of the mice was found.
3.2.2 Qualitative Analysis
The aim of the qualititative analysis was to investigate whether there was a qual-
itative difference in the nile red or nanoparticle distribution in the tumor between
the different treatment groups. To do this, images from the different treatment
groups and from different mice within the same treatment group were compared.
In some cases the brightness and contrast of the image were adjusted, often to
enhance the background of the image. When the purpose of a figure was to directly
compare images, the brightness and contrast were adjusted the same amount for
all images in the figure.
The nile red fluorescence wavelength differs depending on the hydrophobicity of
the molecules that nile red is bound to [15]. This can also be seen in Figure 10.
This property of nile red was used in the qualitative analysis of the images to try
to determine what nile red binds to in the tumor tissue.
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4 Results
The total fluorescence was calculated for every section, and the average total flu-
orescence of all sections was found for each mouse. Subsequently, the average
total fluorescence of all mice in each treatment group was found, in addition to
the standard deviation. These data are presented in Figure 11, which shows the
average total fluorescence per tumor. The figure shows how the total fluorescence
per tumor varies between different treatment groups. Based on the large standard
deviations in Figure 11, there seems to be no difference in fluorescence from mice
having received ultrasound treatment and mice not having received ultrasound
treatment, and no difference between the three different ultrasound treatment
groups.
Figure 11: Average total fluorescence per tumor for the different treatment groups.
US 1 is 1 MHz and MI = 0.1, US 2 is 1 MHz and MI = 0.4 and US 3 is 1 MHz
and MI = 0.4 + 5 MHz and MI = 2.24.
To investigate how the total fluorescence varies between mice within the same
treatment group, the average total fluorescence of all sections from each mouse
was plotted for mice within the same treatment group. These plots are shown
in Figure 12. Each plot in Figure 12 presents data from all mice within one
treatment group, and each bar in the plots represents one mouse. The figure thus
shows how the total fluorescence per tumor varies between different mice from the
same treatment group. Due to the large standard deviations there seems to be no
difference between different mice receiving the same treatment. However, when
Figure 12 is compared to Figure 11 it becomes evident that the variations between
mice within the same treatment groups is even larger than the variation between
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the different treatment groups. Even the variations between different sections
from the same mouse must be very large, judging from the standard deviations in
Figure 12.
(a) No US.
(b) 1 MHz and MI = 0.1 (US 1).
Figure 12: Average total fluorescence per tumor for mice within same treatment
group. Each plot represents one treatment group and each bar in the plots repre-
sents one mouse. (a) shows average total fluorescence for mice having received no
US treatment, and (b) for mice having received US 1.
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(c) 1 MHz and MI = 0.4 (US 2).
(d) 1 MHz and MI = 0.4 + 5 MHz and MI = 2.24 (US 3).
Figure 12: Average total fluorescence per tumor for mice within same treatment
group. Each plot represents one treatment group and each bar in the plots repre-
sents one mouse. (c) shows average total fluorescence for mice having received US
2, and (d) for mice having received US 3.
Before quantitative analysis could be performed on the tile scans, they had to be
linearly unmixed. For some of the tile scans, linear unmixing resulted in an image
where a ”nile red tint” was suddenly introduced that was not present in the original
image. Examples of this are shown in Figure 13. Here, green represents nile red
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bound to fat. From Figure 13 it is obvious that this unmixing error occured to
varying degrees in the different sections. Most sections came out slightly greener
than the original, some images came out intensely green across the entire tile scan,
while in some sections no false nile red was introduced. This introduction of false
nile red in some sections affected further quantitative analysis. As a threshold
is chosen in the matlab routine above which a pixel is counted as fluorescent,
more pixels were counted as fluorescent in the images where a green tint had been
introduced. When it was obvious that the unmixing was erroneous, that section
was excluded from further analysis.
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(a) A lot of false nile red fluorescence has been introduced in the unmixed image. Section is
excluded from further analysis.
(b) Some false nile red fluorescence has been introduced in the unmixed image. Section might be
excluded from further analysis.
(b) No false nile red fluorescence has been introduced in the unmixed image; however, some nile
red fluorescence from the original image has been interpreted as not being nile red bound to fat.
Section is included in further analysis. This tile scan is from the periphery of the tumor and most
likely shows normal tissue instead of tumor tissue.
Figure 13: Confocal tile scans from three different sections, before (top images)
and after (bottom images) unmixing. In the original images, green represents nile
red fluorescence, while in the unmixed images green represents nile red bound to
fat.
To investigate how the nile red fluorescence varies with relative position in the
tumor, line plots of total fluorescence versus relative position in the tile scan were
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made. Figure 14 shows the line plots comparing treatment groups. In this figure,
each graph represents one treatment group. Comparing the four graphs in Fig-
ure 14, there seems to be no real difference between the different treatment groups.
The fluorescence is generally quite low; however, there seems to be a trend indicat-
ing that the fluorescence intensity is higher in the periphery of the tumors and in
some areas further into the tumor. However, the standard deviation is very high
(see Appendix), and hence it cannot be concluded that the fluorescence really is
higher in some areas of the tumor.
Figure 14: Line plots showing average total fluorescence intensity versus relative
position in the tile scan. Each graph represents one treatment group. US 1 is 1
MHz and MI = 0.1, US 2 is 1 MHz and MI = 0.4, and US 3 is 1 MHz and MI =
0.4 + 5 MHz and MI = 2.24. There seems to be no real difference between the
treatment group, except for indications of higher fluorescence in the periphery of
the tumors and in some areas further into the tumor.
Line plots were also made comparing the fluorescence at different positions in the
tumor for the different mice within the same treatment group. These plots are
shown in Figure 15. Figure 15 basically shows the same as Figure 14. In general,
there is not much fluorescence, but there seems to be higher fluorescence in the
periphery of the tumors. There also seems to be higher fluorescence in some areas
further into the tumor sections. Figure 15c stands out as the fluorescence does
not seem to be higher in the periphery, only at certain locations toward the center
of the tumors. The standard deviation is again very high (see Appendix), and as
before it cannot be concluded that the fluorescence is higher in some areas.
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(a) No US.
(b) 1 MHz and MI = 0.1 (US 1).
Figure 15: Line plots showing average total fluorescence intensity versus relative
position in the tile scan. Each graph represents one mouse. (a) shows the average
total fluorescence for mice having received no ultrasound treatment, and (b) for
mice having received US 1.
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(c) 1 MHz and MI = 0.4 (US 2).
(d) 1 MHz and MI = 0.4 + 5 MHz and MI = 2.24 (US 3).
Figure 15: Line plots showing average total fluorescence intensity versus relative
position in the tile scan. Each graph represents one mouse. (c) shows the average
total fluorescence for mice having received US 2, and (d) for mice having received
US 3.
A selection of confocal images are shown in Figures 16, 17, 18 and 19. Each figure
contains six selected images from mice within one treatment group; three from the
periphery of the sections and three from the center of the sections. The images
selected are a representative collection from the tumors in each treatment group.
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The purpose is to qualitatively compare how the nile red distribution is in tumors
from different treatment groups. Figure 16 shows images from mice having received
no ultrasound treatment, and Figures 17, 18 and 19 show images from mice having
received US 1, 2 and 3, respectively. Brightness and contrast have been adjusted
in some of the images. It is evident from the images that the larger green spots, or
”clouds”, that are seen e.g. in Figures 16e, 17e, 18d and 19d are mainly seen in the
periphery of the tumors, although in some cases they can also be observed in the
center of the tumor. When comparing the different treatments, the green clouds
are more intense in the mice that have received ultrasound treatment compared
to the mice that have not received ultrasound treatment. The images from the
mouse that received no nanoparticles and no ultrasound treatment did not contain
any of these clouds. In addition, it seems that the fluorescence in the center of the
tumors is more localized to small, intense, green spots in the mice that received no
ultrasound treatment, whereas the nile red fluorescence seems to be more evenly
distributed in the mice that did receive ultrasound treatment. Some of the images
from the tumor periphery most likely show normal tissue instead of tumor tissue.
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(a) Center. (d) Periphery.
(b) Center. (e) Periphery.
(c) Center. (f) Periphery.
Figure 16: A selection of confocal images from mice having received no ultrasound
treatment.
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(a) Center. (d) Periphery.
(b) Center. (e) Periphery.
(c) Center. (f) Periphery.
Figure 17: A selection of confocal images from mice having received US 1 (1 MHz
and MI = 0.1).
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(a) Center. (d) Periphery.
(b) Center. (e) Periphery.
(c) Center. (f) Periphery.
Figure 18: A selection of confocal images from mice having received US 2 (1 MHz
and MI = 0.4).
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(a) Center. (d) Periphery.
(b) Center. (e) Periphery.
(c) Center. (f) Periphery.
Figure 19: A selection of confocal images from mice having received US 3 (1 MHz
and MI = 0.4 + 5 MHz and MI = 2.24).
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In some of the images in Figures 16, 17, 18 and 19, green fluorescence in a pattern
that looks like cells can be seen in the background. In Figure 20 a selection
of such images are presented. One central image from each treatment group is
included in the figure. In addition, two images from the mouse that received no
nanoparticles and no ultrasound are included in the figure; one image from the
periphery and one from the center of the tumor. The scale bars in the images
show that the background structures are all about 10 µm, a reasonable size for
presumed cells. The brightness and contrast have been adjusted by the same
amount in all of these images to enhance the cell pattern in the background. As
previously mentioned, the nile red seems to be more evenly distributed in the mice
that have received ultrasound treatment. The same cell-like background pattern
arises in the images from the mouse without nanoparticles, indicating that this
pattern could be caused by autofluorescence rather than nile red uptake in cells.
The fluorescence in the mouse without nanoparticles is however less intense than
in the mice with nanoparticles, so some of the fluorescence in these images might
actually be caused by nile red uptake. In the peripheral image of the mouse
without nanoparticles, the fluorescence intensity is a lot stronger. However, this
image most likely shows normal tissue instead of tumor tissue.
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(a) Central section from treat-
ment group without US.
(b) Central section from mouse
receiving US 1 (1 MHz and MI
= 0.1).
(c) Central section from mouse
receiving US 2 (1 MHz and MI
= 0.4).
(d) Central section from mouse
receiving US 3 (1 MHz and MI
= 0.4 + 5 MHz and MI = 2.24).
(e) Peripheral section from
mouse receiving no nanoparti-
cles and no US treatment. Most
likely normal tissue.
(f) Central section from mouse
receiving no nanoparticles and
no US treatment.
Figure 20: Selected central images from mice from all treatment groups, showing
background with cell-like pattern, and peripheral and central image from mouse
without nanoparticles and without ultrasound. Brightness and contrast have been
adjusted by the same amount in all images.
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As seen in Figure 20 some bright spots are seen in the central image from the mouse
without nanoparticles. These bright spots are reminiscent of the bright spots seen
in Figure 20a. The small, intense, green spots that are seen in some of the images
from mice having received no ultrasound, such as Figure 20a, are thought to be
relatively intact nanoparticles. However, it is impossible that the bright, green
spots in Figure 20f are nanoparticles, as no nanoparticles were administered to the
mouse. In hope to understand more about what the different structures that are
seen in the images are, the spectra were extracted from the lambda mode images.
These spectra are shown in Figures 21, 22 and 24.
Figure 21: Spectrum from control mouse without administration of nanoparticles
and without ultrasound. (A) shows lambda mode image, with an arrow pointing
to the structure from which the spectrum was taken. (B) shows a close-up image
of the structure, with an outline of where the spectrum was taken. (C) shows the
spectrum. There is a maximum at around 605 nm, close to the emission wavelength
of the nanoparticles.
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Figure 22: Spectrum from mouse having received nanoparticles, but no ultra-
sound treatment. (A) shows lambda mode image, with an arrow pointing to the
structure from which the spectrum was taken. (B) shows a close-up image of the
structure, with an outline of where the spectrum was taken. (C) shows the spec-
trum. There is a maximum at around 600 nm, close to the emission wavelength of
the nanoparticles. However, the maximum from the mouse without nanoparticles
lies too close to this maximum, hence it cannot be concluded that the structure is
intact nanoparticles.
Figure 21 shows the spectrum of a structure from the mouse that received no
nanoparticles. The channel mode image is shown in Figure 20f. The maximum
of the spectrum lies at around 605 nm. This is slightly above, but quite close
to, the emission wavelength of the nanoparticles (see Figure 10), although it is
impossible that this is nanoparticles as no nanoparticles were administered to the
mouse. Figure 22 shows the spectrum of a structure that is thought to be intact
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nanoparticles. The channel mode image is shown in Figure 20a. The maximum of
the spectrum lies just below 600 nm. This is very close to the emission wavelength
of the nanoparticles, meaning that this structure might in fact be composed of rela-
tively intact nanoparticles. However, since the maxima of the spectra in Figure 21
and Figure 22 lie so close together in wavelength, it is impossible to conclude that
this is in fact nanoparticles and not just an artefact.
Figure 24 shows the spectrum from a green ”cloud”, and the spectrum from another
structure thought to be intact nanoparticles. The maximum of the spectrum from
the cloud is placed at around 590 nm. The spectra of several different clouds were
taken, and they all had maxima at around 590 nm. This is slightly left-shifted
compared to the spectrum of the nanoparticles. The maximum of the spectrum
from the structure thought to be nanoparticles lies at around 605 nm. This is
slightly right-shifted compared to the nanoparticles, but again the maximum lies
too close to that of the artefacts and henceit can not be concluded that this is
nanoparticles. The channel mode version of the image from Figure 24 is shown in
Figure 23.
Figure 23: Channel mode version of the image from which the spectra in Figure 24
were taken.
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Figure 24: Spectra from mouse having received nanoparticles, and US 3. (A) shows
lambda mode image, with an arrow pointing to the structures from which the spec-
tra were taken. (B) and (C) show close-up images of the structures, with outlines
of where the spectra were taken. (D) and (E) show the spectra from structures (B)
and (C), respectively. For structure (B) there is a maximum at around 590 nm.
This is slightly left-shifted compared to the nanoparticles, and might therefore be
nile red bound to fat. For structure (C) there is a maximum at around 605 nm.
Although this is close to the maximum for the nanoparticles, it is too close to
the emission maximum from the mouse having received no nanoparticles, hence it
cannot be concluded that this is intact nanoparticles.
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5 Discussion
5.1 Methods
Image aquisition During tile scan image aquisition, the aim was to take tile
scans from one periphery of the tumor section to the the other periphery, through
the center of the tumor. However, as the tile scan function of the microscope
software has a maximum allowed number of images per tile scan, it is impossible
to take a tile scan through the center of the tumor if the section diameter exceeds
this maximum tile scan length. As several sections were too large, the tile scan of
these sections had to be taken toward the rim of the tumor, where the diameter
was smaller. Hence, several tile scans are instead taken from the topmost or
bottommost positions of the sections.
Along the tumor rim some normal tissue can often be seen; a cap of collagen and
elastin. Some normal tissue will inevitably be included in the tile scans as long as
it is present along the rim of the tumor, and if the tile scan is taken too far toward
the edges, a lot of the tile scan will be of normal tissue instead of tumor tissue. It
is evident from the images in this study that the cap has a lot of autofluorescence
compared to the tumor tissue, and this high fluorescence will affect the analysis.
Tile scans taken at or close to the tumor rim will be significantly more fluorescent
than tile scans taken through the center of the tumor. The normal tissue is most
likely also part of the reason why the fluorescence intensity in the periphery of the
tumors seems to be higher in the line plots in Figures 14 and 15.
The statistics of the quantitative analysis would most likely have been significantly
improved if all tile scans had been taken through the center of the tumor, and if
the normal tissue along the rim of the tumor had not been present, as the standard
deviations would have been reduced. Had the standard deviations been smaller, the
differences between different treatment groups could possibly have been significant.
However, it is also possible that the small differences would completely disappear.
Linear unmixing As previously mentioned, false nile red fluorescence was in-
troduced to several of the tile scans during linear unmixing. This was probably
caused by the fact that the recorded reference spectra that were used for linear
unmixing were not good enough. If an unreasonable amount of pixels in a tile
scan were counted as fluorescent, the tile scan was excluded from further analysis.
However, as was seen in Figure 13, this erroneous unmixing occured at varying
degrees for different tile scans. It is hard to tell whether some false fluorescence
was introduced to all of the sections, or just to a few of them, and deciding which
tile scans should be allowed in the analysis and which should not, is challenging.
If too many tile scans are excluded, the statistics of the analysis suffer, but if too
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many are included, the standard deviations become unreasonably high. This is
probably part of the reason why the standard deviations are so high in this study.
Matlab For the Matlab routine, one single threshold value was chosen for all the
sections that were analyzed. This was done to save time, as it would have been
extremely time consuming to find a good threshold value separately for each of close
to 100 tile scans. However, using a common threshold value for all the sections
was not ideal as the autofluorescence level varies between mice, and because of
the false nile red fluorescence introduced during linear unmixing. The threshold
worked quite well for some sections, but for several of the sections the threshold
was either too low, so that pixels were counted that were actually background, or
too high, so that not all fluorescent pixels were counted. Adjusting the threshold
value might lead to an improvement of the problem. However, a lower threshold
value would lead to poorer statistics as more sections would have to be excluded,
whereas a higher threshold value would lead to even fewer pixels being counted in
the images where too few pixels are counted already. Finding a middle ground that
works as well as possible for as many of the tile scans as possible, is challenging.
5.2 Effect of Ultrasound Treatment
Quantitative Analysis No statistically significant difference is observed be-
tween the different treatment groups in the quantitative analysis, due to the very
large standard deviations. It is important to stress that although no significant dif-
ference is found, this does not necessarily mean that there is no difference between
the groups. The standard deviations between mice within the same treatment
group, and even between different sections from the same mouse, show that the
fluorescence varies just as much, if not more, between sections and between mice
as it does between treatment groups. As the large standard deviations are prob-
ably due to poor reference spectra for unmixing and normal tissue at the tumor
rim, using better spectra and recording better tile scans might give vastly different
results.
The plots of average total fluorescence versus relative position in the tumor, pre-
sented in Figures 14 and 15, indicate that the fluorescence might be higher at
peripheral positions in the tumor. This indication might merely be a result of the
normal tissue at the tumor rim being a part of the tile scans. If this is the case,
the line plots no longer correctly reflect the distribution of nile red in tumor tissue.
The high fluorescence in peripheral positions might also partly be caused by the
large, intense, green spots, or ”clouds”, that are seen in some images, as they are
found mainly in the tumor periphery and contribute with a large amount of nile
red fluorescence.
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In general, the florescence in the tile scans is quite low. This could be due to a too
small amount of nile red encapsulated in the nanoparticles, or because nile red is
not a well-suited dye for this purpose. Similar nanoparticles have previously been
found to be leaking nile red [47]. The overall fluorescence would probably have
been higher if the threshold was lower, but that would again mean that more plots
would have to be excluded from the analysis.
Qualitative Analysis Although there is no significant quantitative difference
between the treatment groups, there are two qualitative differences between the
mice that have received ultrasound treatment and the mice that have not. The
differences can be observed from the images taken with the 63x/1.4 oil objective.
The first difference is related to the fluorescent ”clouds” that are observed in the
periphery of the tumors. The clouds are much more intense in the mice that have
been treated with ultrasound than in the mice that only have had nanoparticles
intravenously administered, but have received no ultrasound treatment. There is
no pronounced difference between the clouds in images from mice having received
different ultrasound treatments. As the emission spectra of nile red can vary with
what nile red is bound to [15]. Nile red spectra are shifted toward shorter wave-
lengths when the polarity of the solvent decreases [14]; hence, they are shifted
toward shorter wavelengths when nile red is bound to a hydrophobic substance. It
it seen from Figure 24 that the spectra of these clouds are slightly left-shifted com-
pared to the emission wavelength of the nanoparticles (Figure 10, with a maximum
from the clouds at around 590 nm. Hence, it is thought that these clouds might
be nile red bound to adipose tissue, which is hydrophobic. Pugliese et al. [43] have
shown that ultrasound can lead to alterations in adipocytes and collagen fibers.
Thus, the clouds might appear brighter because something happens with the adi-
pose tissue during ultrasound treatment so that more nile red is taken up. It is also
possible that the clouds appear brighter because the ultrasound treatment affects
the nanoparticles themselves to make them release more nile red, or it could be a
combination of both effects. The clouds were not observed in any of the images
from the mouse that did not receive nanoparticles. This is an indication that the
clouds are indeed caused by free nile red binding to adipose tissue.
The second difference is that the nile red fluorescence in Figure 20, where there
appears to be cells in the background, is more diffuse in the mice that have re-
ceived ultrasound treatment. Some of this diffuse fluorescence could be due to
autofluorescence. However, since the background in the mice that have received
nanoparticles and ultrasound has a higher fluorescence intensity than that of the
mouse without nanoparticles, it could also be partly due to uptake of nile red in
cells. It was attempted to obtain an emission spectrum from what was thought
to be the inside of the cells. This was challenging, as the spectrum changed at
even the slightest relocation of where the spectrum was taken from. This could
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be a sign that nile red binds to many different molecules inside the cells and in
the tissue, since the nile red spectra vary with the hydrophobicity of the substance
that nile red is bound to. As nile red is hydrophobic [15], it would more likely
bind to hydrophobic molecules inside the cell than to be free in the cytosol. The
fact that the spectrum changes so much could therefore be an indication that nile
red is in fact taken up into cells, although it is impossible to draw a conclusion. If
nile red is taken up in the cell, it is probably free nile red that has been released
from the nanoparticle. Free nile red could be released as a result of the ultra-
sound treatment, but is could also be released as a result of natural degradement
of the nanoparticles in the tumor tissue, or it could be a result of the nanoparticles
leaking nile red.
Small, intensely colored, green spots were observed both in the mice that received
no ultrasound, and in the mouse that received no nanoparticles and no ultrasound.
These spots were thought to be relatively intact nanoparticles. The spectra of
the structures were extracted to check this assumption. It turned out that the
spectrum maximum of the structure from the mouse that received nanoparticles
without ultrasound coincides with the emission wavelength of the nanoparticles at
just below 600 nm, meaning that the spots might be intact nanoparticles. However,
the maximum also lies close to the maximum of the artefact spectrum from the
mouse that received no nanoparticles. The maximum of the emission spectrum
for the artefacts might incidentally lie very close to the nanoparticle spectrum,
in which case it is still possible that the green spots in the treated mice are in
fact nanoparticles, but no certain conclusion can be made. This could also be an
indication that the recorded spectra for linear unmixing are not good enough.
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6 Conclusions and Further Work
The quantitative analysis resulted in no statistically significant differences between
the different treatment groups. The differences between different mice within the
same treatment group, and even between different sections from the same mouse,
were just as large, if not larger. However, a qualitative difference between the
mice that did not receive ultrasound and the mice that did receive ultrasound was
found. The mice that received ultrasound had bright, green spots or ”clouds” of
much higher intensity than the mice that did not receive ultrasound. The mouse
that did not receive nanoparticles showed no such clouds. This indicates that the
fluorescence from these clouds does come from nile red. Based on the emission
spectra, they are thought to be nile red bound to fat. Since the clouds are brighter
in mice with ultrasound, nile red must somehow be taken up to a higher degree in
fat tissue with ultrasound. Whether this is a result of a change in the fat tissue as
a response to the ultrasound or a result of more nile red being released from the
nanoparticles as a response to the ultrasound, is not known.
In the future, a different dye than nile red should be used in the nanoparticles, as
nile red has been shown to leak out of nanoparticles similar to the ones used in
this study. In addition, the nanoparticles used should have a higher fluorescence
than the autofluorescence of the mice, so that the autofluorescence is not such a
big issue. Better spectra should be taken so that the linear unmixing does not
introduce false fluorescence, but rather removes autofluorescence as it is supposed
to, and better tile scans should be taken so that they pass through the center of
the tumor and do not include such a large amount of normal tissue.
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Appendix
Tables show data that were used to produce line plots of total fluorescence versus
relative position. The standard deviations are very large.
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